|Support type:||Scholarships in Brazil - Master|
|Effective date (Start):||December 01, 2015|
|Effective date (End):||November 30, 2017|
|Field of knowledge:||Health Sciences - Medicine|
|Principal Investigator:||Andrey Jorge Serra|
|Grantee:||Rafael Do Nascimento de Lima|
|Home Institution:||Universidade Nove de Julho (UNINOVE). Campus Vergueiro. São Paulo , SP, Brazil|
Anthracyclines are chemotherapeutic agents widely used in the treatment of hematologic malignancies and cancer. Among these, doxorubicin (DOXO) takes a prominent position. It is worth mentioning, however, that this alternative therapy can cause cellular damage of great magnitude, particularly in cardiomyocytes, persisting even after the duration of drug use. In these cases, the advance for heart failure (HF) is not uncommon. Because of these implications, the use of different treatment options to slow down the effects of Doxo the heart was tested as therapy with stem cells, which had already shown interest in the treatment of HF due to other events. However, the positive expectations with the use of cell therapy to IC due to the use of DOXO are mitigated by the toxicity of the drug, which can cause a dramatic reduction of cell survival after transplantation. The purpose of this project is testing the use of laser therapy of low intensity (LLLT) in this scenario, where its effects will be analyzed as preconditioning tool to increase resistance to Doxo of mesenchymal stem cells in culture. Therefore, it will be initially performed a pilot study in order to choose the dose of Doxo can result in the death of approximately 50% of the cultured cells. Then proceed with treatment with 3 different doses laser in cultures incubated with the dose something Doxo and viability analysis and cell proliferation, as well as apoptosis and oxidative stress.